Greenwich LifeSciences, Inc.
NASDAQ:GLSIBiotechnology
-$0.74 today
- Market cap
- $302.08M
- Beta
- 1.38
- P/E (TTM)
- -15.6
- EPS (TTM)
- -$1.49
Volume 0.71M
Average 0.14M
GLSI Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Greenwich LifeSciences, Inc.NASDAQ: GLSI
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue remains negative
Q1 FY2026 revenue was $0, compared with $0 a year earlier. Trailing-twelve-month revenue was $0.
Context
- Revenue increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Revenue history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Revenue vs competitors
How GLSI compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $123.87M USD | +24.5% | +5.2% | |
| LTM Mar 2026 | $15.04M USD | -0.9% | +3.2% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $11.98M USD | -12.2% | -29.1% |
| LTM Mar 2026 | $7.49M USD | -35.6% | -34.7% | |
| LTM Mar 2026 | $0 USD | — | — | |
| LTM Mar 2026 | $0 USD | — | — | |
| LTM Mar 2026 | $0 USD | — | — | |
| LTM Mar 2026 | $0 USD | — | — | |
| LTM Mar 2026 | CA$0 CAD | — | — | |
| Peer median (excluding GLSI) | — | -6.5% | -13.0% | |
Competitors are the stored peer set for GLSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 3.61K | 3.61K | 3.61K | 3.61K | 1.78K |
| Gross Profit | (3.61K) | (3.61K) | (3.61K) | (3.61K) | (1.78K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 3.56M | 6.48M | 7.7M | 15.48M | 17.22M |
| Selling, General & Admin | 1.04M | 1.56M | 1.63M | 2.15M | 2.23M |
| Operating Expenses | 4.59M | 8.04M | 9.32M | 17.63M | 19.45M |
| Depreciation & Amortization | 3.61K | 3.61K | 3.61K | 3.61K | 1.78K |
| EBITDA | (4.57M) | (7.82M) | (8.89M) | (17.41M) | (19.36M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (4.6M) | (8.04M) | (9.33M) | (17.64M) | (19.45M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 27.37K | 215.02K | 436.06K | 223.01K | 89.7K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 27.37K | 215.02K | 436.06K | 223.01K | 89.7K |
| Income Before Tax | (4.57M) | (7.83M) | (8.89M) | (17.41M) | (19.36M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (4.57M) | (7.83M) | (8.89M) | (17.41M) | (19.36M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.35) | (0.61) | (0.69) | (1.21) | (1.43) |
| EPS (Diluted) | (0.35) | (0.61) | (0.69) | (1.21) | (1.43) |
| Weighted Avg Shares | 12.94M | 12.91M | 12.85M | 13.01M | 13.53M |
| Weighted Avg Shares (Diluted) | 12.94M | 12.91M | 12.85M | 13.01M | 13.53M |
Greenwich LifeSciences, Inc.
NASDAQ:GLSI
Intrinsic Alpha fair value
Locked
Current Price
$20.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.